2573-8348

Cancer Reports

Wiley (John Wiley & Sons)

View prefix report (10.1002)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 203 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact203 DOIs
2

Deposit reference lists for 186 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact186 DOIs
3

Add abstracts to 169 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact169 DOIs

DOIs for this ISSN

Showing the top 5 of 1611 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 <scp>PD</scp>‐1 blockade using pembrolizumab in adolescent a… (10.1002/cnr2.1327)
ORCID
27.85 12
2 Targeting regulatory T cells for improving cancer therapy: C… (10.1002/cnr2.1105)
ORCID
26.03 10
3 Lactic acidosis, a potential toxicity from drug–drug interac… (10.1002/cnr2.1575)
ORCID
26.03 10
4 Real‐world data prognostic model of overall survival in pati… (10.1002/cnr2.1578)
ORCID
23.86 8
5 Unraveling immunotherapy's role in propelling cancer outcome… (10.1002/cnr2.1862)
Abstract ORCID
23.86 2
6 Bridging racial and ethnic disparities in cancer research (10.1002/cnr2.1871)
Abstract ORCID
23.86 2
7 Introducing <i>Cancer Reports</i> – The Concept, Execution a… (10.1002/cnr2.1109)
Abstract References ORCID
22.58 1
8 Observational, prospective, phase 4 study in patients with f… (10.1002/cnr2.1467)
ORCID
21.13 6
9 The patient experience of relapsed refractory multiple myelo… (10.1002/cnr2.1603)
ORCID
21.13 6
10 Gastrointestinal perforation associated with bevacizumab in… (10.1002/cnr2.1952)
ORCID
21.13 6
11 Emerging concepts in cancer therapy: Mechanisms of resistanc… (10.1002/cnr2.1715)
Abstract
17.47 4
12 Advances and challenges in pediatric cancers (10.1002/cnr2.1202)
Abstract
15.05 3
13 Conditional disease‐free survival rates and their associated… (10.1002/cnr2.1416)
ORCID
15.05 3
14 The cost, survival, and quality‐of‐life implications of <scp… (10.1002/cnr2.1468)
ORCID
15.05 3
15 Treatment patterns and outcomes in older patients with advan… (10.1002/cnr2.1568)
ORCID
15.05 3
16 Brain metastasis: The next steps for translational research (10.1002/cnr2.1623)
Abstract ORCID
15.05 1
17 Patient‐led research and Advocacy Efforts (10.1002/cnr2.1657)
Abstract ORCID
15.05 1
18 Comparing the rate of immunotherapy treatment change due to… (10.1002/cnr2.1932)
ORCID
15.05 3
19 Impact of pathological response after neoadjuvant chemothera… (10.1002/cnr2.1412)
ORCID
11.93 2
20 Risk factors and clinical outcomes of systemic cancer treatm… (10.1002/cnr2.1426)
ORCID
11.93 2
21 Comparison of the Efficacy and Safety of <scp>PD</scp>‐1/<sc… (10.1002/cnr2.70081)
ORCID
11.93 2
22 The Impact of a Positive Body Image Program (Body Image Awar… (10.1002/cnr2.70161)
ORCID
11.93 2
23 Understanding the mechanistic features of cancer metastasis (10.1002/cnr2.1238)
Abstract
7.53 1
24 Determination of <i>ERG</i>(+), <i>EZH2</i>, <i>NKX3.1</i>,… (10.1002/cnr2.1728)
ORCID
7.53 1
25 Outcomes after primary intensity‐modulated radiation therapy… (10.1002/cnr2.1001)
0.00 1
26 <scp>CD8</scp> lymphocytes in tumors and nonsynonymous mutat… (10.1002/cnr2.1002)
0.00 8
27 How do cancer cells replenish their fuel supply? (10.1002/cnr2.1003)
0.00 3
28 Differentially localized survivin and <scp>STAT3</scp> as ma… (10.1002/cnr2.1004)
0.00 9
29 Chemotherapy dosing and toxicity in a patient with muscular… (10.1002/cnr2.1106)
0.00 4
30 Favourable outcomes for childhood acute lymphoblastic leukae… (10.1002/cnr2.1107)
0.00 2
31 Quantitative assessment of changes in diffusion tensor imagi… (10.1002/cnr2.1108)
0.00 4
32 <scp>WT‐CLS1</scp> is a rhabdoid tumor cell line and can be… (10.1002/cnr2.1110)
0.00 5
33 Aberrant DNA methylation at <i>HOXA4</i> and <i>HOXA5</i> ge… (10.1002/cnr2.1111)
0.00 13
34 Issue Information (10.1002/cnr2.1112)
References ORCID
0.00 0
35 Issue Information (10.1002/cnr2.1113)
References ORCID
0.00 0
36 Issue Information (10.1002/cnr2.1114)
References ORCID
0.00 0
37 Issue Information (10.1002/cnr2.1115)
References ORCID
0.00 0
38 Issue Information (10.1002/cnr2.1118)
References ORCID
0.00 0
39 Issue Information (10.1002/cnr2.1119)
References ORCID
0.00 0
40 Issue Information (10.1002/cnr2.1120)
References ORCID
0.00 0
41 Issue Information (10.1002/cnr2.1121)
References ORCID
0.00 0
42 Issue Information (10.1002/cnr2.1122)
References ORCID
0.00 0
43 Cover Image (10.1002/cnr2.1123)
Abstract References ORCID
0.00 0
44 Clinical study of asbestos‐related lung cancer diagnosed by… (10.1002/cnr2.1124)
0.00 4
45 Expression of human papillomavirus oncoproteins E6 and E7 in… (10.1002/cnr2.1125)
0.00 2
46 Progressive breast fibrosis caused by extreme radiosensitivi… (10.1002/cnr2.1126)
0.00 2
47 Oncologist perspectives on chemotherapy‐induced nausea and v… (10.1002/cnr2.1127)
0.00 32
48 Overview of antiproton affinities for functional groups rele… (10.1002/cnr2.1128)
0.00 0
49 Sigmoid colon perforation after postoperative hypofractionat… (10.1002/cnr2.1129)
0.00 2
50 Molecular investigation of <i>FGFR3</i> gene mutation and it… (10.1002/cnr2.1130)
0.00 7